Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer

Urologic Clinics of North America

Volumn 34, Issue 2, 2007, Pages 137-148

  Choueiri, Toni K ^a   Stephenson, Andrew J ^b   Gilligan, Timothy ^a   Klein, Eric A ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; VINBLASTINE; VINCRISTINE;

CANCER STAGING; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; HEARING LOSS; HUMAN; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; ORCHIECTOMY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TESTIS CARCINOMA;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHORIONIC GONADOTROPIN; CLINICAL TRIALS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247619266     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.02.001     Document Type: Review

References (65)

1. Sheinfeld J. Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology 44 1 (1994) 2-14
2. Donohue J.P., Zachary J.M., and Maynard B.R. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128 (1982) 315-320
3. Leibovitch L., Foster R.S., Kopecky K.K., et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154 5 (1995) 1759-1763
4. Hilton S., Herr H.W., Teitcher J.B., et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169 2 (1997) 521-525
5. Albers P., Siener R., Kliesch S., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21 8 (2003) 1505-1512
6. Alexandre J., Fizazi K., Mahe C., et al. Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37 5 (2001) 576-582
7. Heidenreich A., Sesterhenn I.A., Mostofi F.K., et al. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83 5 (1998) 1002-1011
8. Hermans B.P., Sweeney C.J., Foster R.S., et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163 6 (2000) 1721-1724
9. Nicolai N., Miceli R., Artusi R., et al. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171 1 (2004) 172-176
10. Roeleveld T.A., Horenblas S., Meinhardt W., et al. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166 6 (2001) 2166-2170
11. Sogani P.C., Perrotti M., Herr H.W., et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159 3 (1998) 855-858
12. Stephenson A.J., Bosl G.J., Motzer R.J., et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23 12 (2005) 2781-2788
13. Sweeney C.J., Hermans B.P., Heilman D.K., et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 18 2 (2000) 358-362
14. Vergouwe Y., Steyerberg E.W., Eijkemans M.J., et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21 22 (2003) 4092-4099
15. Leibovitch I., Foster R.S., Kopecky K.K., et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16 1 (1998) 261-268
16. Colls B.M., Harvey V.J., Skelton L., et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 83 1 (1999) 76-82
17. Francis R., Bower M., Brunstrom G., et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36 15 (2000) 1925-1932
18. Gels M.E., Hoekstra H.J., Sleijfer D.T., et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13 5 (1995) 1188-1194
19. Sharir S., Jewett M.A., Sturgeon J.F., et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161 2 (1999) 472-475 [discussion: 5-6]
20. Daugaard G., Petersen P.M., and Rorth M. Surveillance in stage I testicular cancer. APMIS 111 1 (2003) 76-85
21. Hao D., Seidel J., Brant R., et al. Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 160 3 Pt 1 (1998) 768-771
22. Foster R.S., Baniel J., Leibovitch I., et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 155 6 (1996) 1943-1945
23. Sheinfeld J., Motzer R.J., Rabbani F., et al. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol 170 4 Pt 1 (2003) 1159-1162
24. Toner G.C., Panicek D.M., Heelan R.T., et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8 10 (1990) 1683-1694
25. Donohue J.P., and Foster R.S. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 25 3 (1998) 461-468
26. Donohue J.P., Thornhill J.A., Foster R.S., et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 71 3 (1993) 326-335
27. Amato R.J., Ro J.Y., Ayala A.G., et al. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63 1 (2004) 144-148 [discussion: 8-9]
28. Williams S.D., Stablein D.M., Einhorn L.H., et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317 23 (1987) 1433-1438
29. Donohue J.P., Thornhill J.A., Foster R.S., et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A 10 (1995) 1599-1604
30. Socinski M.A., Garnick M.B., Stomper P.C., et al. Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease. J Urol 140 6 (1988) 1437-1441
31. Kondagunta G.V., Sheinfeld J., Mazumdar M., et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22 3 (2004) 464-467
32. Behnia M., Foster R., Einhorn L.H., et al. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. The Indiana University experience. [see comment]. Eur J Cancer 36 4 (2000) 472-475
33. Baniel J., Foster R.S., Rowland R.G., et al. Complications of primary retroperitoneal lymph node dissection. J Urol 152 2 Pt 1 (1994) 424-427
34. McLeod D.G., Weiss R.B., Stablein D.M., et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 145 6 (1991) 1178-1183 [discussion: 82-3]
35. Richie J.P. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144 5 (1990) 1160-1163
36. Jewett M.A. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 17 2 (1990) 449-456
37. Bhayani S.B., Ong A., Oh W.K., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 62 2 (2003) 324-327
38. Janetschek G., Hobisch A., Peschel R., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 163 6 (2000) 1793-1796
39. Nelson J.B., Chen R.N., Bishoff J.T., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 54 6 (1999) 1064-1067
40. Janetschek G. Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 28 1 (2001) 107-114
41. Donohue J.P., Thornhill J.A., Foster R.S., et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149 2 (1993) 237-243
42. Cullen M., and James N. Adjuvant therapy for stage I testicular cancer. Cancer Treat Rev 22 4 (1996) 253-264
43. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14 4 (1996) 1106-1113
44. Bohlen D., Borner M., Sonntag R.W., et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161 4 (1999) 1148-1152
45. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 9 (2004) 1377-1399
46. Read G., Stenning S.P., Cullen M.H., et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10 11 (1992) 1762-1768
47. Freedman L.S., Parkinson M.C., Jones W.G., et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2 8554 (1987) 294-298
48. Oliver R.T., Ong J., Shamash J., et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 63 3 (2004) 556-561
49. Ondrus D., Matoska J., Belan V., et al. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33 6 (1998) 562-566
50. Chevreau C., Mazerolles C., Soulie M., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46 2 (2004) 209-214 [discussion: 14-5]
51. Abratt R.P., Pontin A.R., Barnes R.D., et al. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S Afr Med J 84 9 (1994) 605-607
52. Pont J., De Santis M., Albrecht W., et al. Risk-adapted management for clinical stage I nonseminomatous germ cell cancer of the testis (NSGCT I) by regarding vascular invasion (VI): A-17 year experience from the Vienna Testicular Tumor Study Group. Proceedings of the American Society of Clinical Oncology 22 (2003) 388
53. Dearnaley D.P., Fossa S.D., Kaye S.B., et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 92 12 (2005) 2107-2113
54. Kollmannsberger C., Kuzcyk M., Mayer F., et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17 4 (1999) 275-281
55. Nuver J., Smit A.J., Wolffenbuttel B.H.R., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. [see comment]. J Clin Oncol 23 16 (2005) 3718-3725
56. Raghavan D., Cox K., Childs A., et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10 9 (1992) 1386-1389
57. Bokemeyer C., Berger C.C., Kuczyk M.A., et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14 11 (1996) 2923-2932
58. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 8 (2000) 1725-1732
59. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 8 (2003) 1513-1523
60. van den Belt-Dusebout A.W., Nuver J., de Wit R., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24 3 (2006) 467-475
61. Berger C.C., Bokemeyer C., Schneider M., et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A 13-14 (1995) 2229-2238
62. Vogelzang N.J., Bosl G.J., Johnson K., et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95 3 (1981) 288-292
63. Weijl N.I., Rutten M.F., Zwinderman A.H., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18 10 (2000) 2169-2178
64. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 18 (2005) 1354-1365
65. Travis L.B., Andersson M., Gospodarowicz M., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92 14 (2000) 1165-1171